Trevi Therapeutics' Haduvio: A Glimmer of Hope for Chronic Cough Sufferers? Trevi Therapeutics' recent stock price surge has raised eyebrows among investors and analysts.
At a European conference, the company's CEO, Jennifer Good, and Chief Development Officer, James Cassella, touted their oral treatment candidate, Haduvio, as a promising solution for patients with refractory chronic cough or idiopathic pulmonary fibrosis.
According to Trevi Therapeutics' presentation, clinical trials showed that Haduvio significantly reduced cough episodes.